HBOT in surgical wound healing: what the new Cureus review means for programs
New Cureus narrative review covers HBOT across chronic wounds, diabetic ulcers, burns, radiation damage, grafts, flaps, and reconstructive salvage.
A March 2026 structured narrative review in Cureus synthesized evidence on HBOT across surgical wound healing and tissue salvage — pulling from PubMed and MEDLINE, January 2000 through February 2026. The mechanisms are familiar to anyone who has run a wound-care program: enhanced plasma-dissolved oxygen delivery, angiogenesis stimulation, fibroblast proliferation, collagen synthesis, and immunomodulation. What matters is the scope of clinical support the review documents: chronic ischemic wounds, diabetic foot ulcers, venous leg ulcers, burn injuries, radiation-induced tissue damage, compromised grafts, ischemic flaps, traumatic soft-tissue injuries, and breast reconstruction salvage.
Reported outcomes include enhanced tissue viability, reduced necrosis progression, improved graft integration, and decreased amputation rates in high-risk populations. That is a broader footprint than many wound-care programs treat today — meaning many hospitals and specialty centers are leaving evidence-based benefit on the table.
For practitioners, the question is throughput and reliability. A chamber that treats one wound-care patient a day is easy. A chamber that runs eight sessions daily for a full multidisciplinary program requires build quality, service response, and pressure-cycle durability that most consumer-grade chambers cannot sustain.
Prestige Hyperbaric supplies hospital-grade chambers for programs treating the conditions in this review. Our installation team handles site prep, code compliance, and staff orientation, and our service team is real people you can reach. If your program is expanding into reconstructive or wound-care territory, talk to us at prestigehyperbaric.com.
Source: Cureus